Tuan Tu Diep - Oct 28, 2024 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Role
Chief Development Officer
Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Stock symbol
SKYE
Transactions as of
Oct 28, 2024
Transactions value $
$0
Form type
4
Date filed
10/30/2024, 08:33 PM
Previous filing
Mar 4, 2024
Next filing
Nov 20, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Stock Option (Right to Buy) Award $0 +125K $0.00 125K Oct 28, 2024 Common Stock 125K $5.15 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests in equal monthly installments over the four year period beginning October 28, 2024.